The bill, known as the “Biosimilars Access and Affordability Act,” proposes changes to the Social Security Act regarding when biosimilar biological products can be subject to price negotiations under the Medicare program. It modifies specific sections to allow for extensions and delays in...
Simple Explanation
The bill suggests changing some rules about how and when the government can talk with companies about the prices of certain medicines that are like copies of existing ones, known as biosimilars, to make sure they don't cost too much. It also adds rules that could charge companies money if they don't sell these copy-medicines when they said they would start.